Clinical

Dataset Information

0

Phase II study of FOLFIRI+biweekly cetuximab for KRAS wild type unresectable colorectal cancer.

ABSTRACT: Primary outcome(s): Response rate

DISEASE(S): Unresectable Colorectal Cancer

PROVIDER: 2626735 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Unknown Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer.
| S-EPMC6113428 | biostudies-literature
Clinical Phase IIstudy of biweekly FOLFIRI+cetuximab treatment for unresectable KRAS-wild type colorectal cancer
| 2626734 | ecrin-mdr-crc
Unknown Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID).
| S-EPMC11002633 | biostudies-literature
Unknown Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study).
| S-EPMC4251687 | biostudies-literature
Unknown Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
| S-EPMC10507485 | biostudies-literature
Unknown Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with KRAS/NRAS/BRAF Wild-Type Colorectal Cancer.
| S-EPMC10249423 | biostudies-literature
Unknown A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer.
| S-EPMC10020809 | biostudies-literature
Unknown Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.
| S-EPMC4119993 | biostudies-literature
Unknown Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer.
| S-EPMC6852115 | biostudies-literature
Unknown Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II Trial.
| S-EPMC7794191 | biostudies-literature